Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

What Was Tested

In this phase 4 trial, researchers set out to test Tirzepatide and Semaglutide.

Semaglutide and tirzepatide are potent obesity medications.

The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

It had two arms (groups): Weight loss medication and standard lifestyle intervention (experimental) and Standard lifestyle intervention only (active comparator).

Subjects will receive tirzepatide or semaglutide in combination with a standard lifestyle intervention.

Subjects will receive standard of care lifestyle intervention only.

The registry classes the interventions as behavioral and drug.

Who Took Part

Enrollment: 30 planned participants were the target.

It was open to women only aged from 46 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy). Age 46-60 years old. BMI ≥ 30 kg/m2.

The full record lists 3 inclusion and 17 exclusion criteria; among the exclusions: past or current use of menopausal hormone therapy; early or premature menopause; history of chemically induced menopause.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Only one side, usually the participants, was kept unaware of whether Tirzepatide was given.

Those kept unaware of assignments: outcomes assessor.

It started in 2025-05-01 with completion listed for 2026-12-31.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Physical Function Measure: Short Physical Performance Battery (SPPB) score (time frame: 24 weeks). Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST) (time frame: 24 weeks). Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST) (time frame: 24 weeks).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide and Semaglutide in 30 people.

Its size is small, so on its own it can only give an early look.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.